Aurisco Pharmaceutical (605116.SH): Currently, there is no collaboration with Novo-Nordisk A/S.

On November 28, Glonghui reported that aurisco pharmaceutical (605116.SH) stated on the investor interaction platform that the company is actively developing the market for the active pharmaceutical ingredient semaglutide, and currently has no collaboration with novo-nordisk a/s.

Gelonghui FinanceNov 28 04:39 ET

Sector Update: Health Care Stocks Advance Wednesday Afternoon

MT NewswiresNov 27 13:42 ET

LLY, NVO Stock Up as Biden Proposes Medicare Cover for Obesity Drugs

Zacks Nov 27 09:00 ET

Novo Nordisk, KKR Joint Acquisition of Sylvan Gets EU Greenlight

MT NewswiresNov 27 08:30 ET

Express News | Novo Nordisk Says Health Canada Approves Wegovy (Semaglutide Injection) To Reduce Risk Of Non-Fatal Myocardial Infarction

BenzingaNov 27 07:07 ET

Will weight loss drugs be included in the US medical insurance, becoming the strongest "roadblock" for the Trump team?

The "Dual Weight Loss Champions" led the significant rise.

Gelonghui FinanceNov 26 20:45 ET